Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection

References

• Bos R, Rutten L, van der Lubbe JE, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5(1):1–11. doi:10.1038/s41541-020-00243-x
   Web of Science ®Google Scholar
• Abebe EC, Dejenie TA, Shiferaw MY, et al. The newly emerged COVID-19 disease: a systemic review. Virol J. 2020;17(1):1–8. doi:10.1186/s12985-020-01363-5
   PubMed Web of Science ®Google Scholar
• Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2020;39:1–10.
   Web of Science ®Google Scholar
• Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020;27:1–4.
   Web of Science ®Google Scholar
• Guihot A, Litvinova E, Autran B, et al. Cell-mediated immune responses to COVID-19 infection. Front Immunol. 2020;11:1662. doi:10.3389/fimmu.2020.01662
   PubMed Web of Science ®Google Scholar
• Malik JA, Ahmed S, Shinde M, et al. The impact of COVID-19 on the comorbidities: a review of recent updates for combating it. Saudi J Biol Sci. 2022;29(5):3586–3599. doi:10.1016/j.sjbs.2022.02.006
   Web of Science ®Google Scholar
• England PH. SARS-CoV-2 variants of concern and variants under investigation in England. Tech Brief; 2021:12.
   Google Scholar
• World Health Organization. Weekly epidemiological update on COVID-19; 2022.
   Google Scholar
• Lauring AS, Malani PN. Variants of SARS-CoV-2. JAMA. 2021;326(9):880. doi:10.1001/jama.2021.14181
   Web of Science ®Google Scholar
• Liu Y, Zhang N, Wang B, et al. Broad and long-lasting immune response against SARS-CoV-2 omicron and other variants by PIKA-adjuvanted recombinant SARS-CoV-2 Spike (S) protein subunit vaccine (YS-SC2-010). bioRxiv. 2021. doi:10.1101/2021.12.22.473615
   Google Scholar
• Center for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions; 2021.
   Google Scholar
• World Health Organization. Tracking SARS-CoV-2 variants; 2022.
   Google Scholar
• Dudas G, Hong SL, Potter BI, et al. Emergence and spread of SARS-CoV-2 lineage B. 1.620 with variant of concern-like mutations and deletions. Nat Commun. 2021;12(1):1–12. doi:10.1038/s41467-021-26055-8
   Web of Science ®Google Scholar
• World Health Organization. Update on Omicron; 2021.
   Google Scholar
• Hanson. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021.
   Google Scholar
• Goodman B. New studies bring BA.2 variant into sharper focus; 2022.
   Google Scholar
• World Health Organization. COVID-19 weekly epidemiological update, Edition 77; 2022.
   Google Scholar
• G Mcgregor. “What is ‘stealth Omicron’? The rise of the subvariant is alarming some scientists who say it needs its own Greek letter. Fortune; 2022.
   Google Scholar
• He X, Hong W, Pan X, et al. SARS‐CoV‐2 Omicron variant: characteristics and prevention. MedComm. 2021;2(4):838–845. doi:10.1002/mco2.110
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Science brief: omicron (B. 1.1. 529) variant; 2021.
   Google Scholar
• Bhoye S, Marakwad T. A comparative characteristics of both variants of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): delta and Omicron; 2021.
   Google Scholar
• Haseltine WA. Omicron Origin. Forbes; 2021.
   Google Scholar
• Cookson C, Barnes O. What we know about Omicron variant that has sparked global alarm. The Financial Times; 2021.
   Google Scholar
• Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600(7887):21. doi:10.1038/d41586-021-03552-w
   PubMed Web of Science ®Google Scholar
• Chen J, Wang R, Gilby NB, et al. Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412–422. doi:10.1021/acs.jcim.1c01451
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–484.e15. doi:10.1016/j.cell.2021.12.046
   PubMed Web of Science ®Google Scholar
• Kumar S, Thambiraja TS, Karuppanan K, et al. Omicron and delta variant of SARS‐CoV‐2: a comparative computational study of spike protein. J Med Virol. 2021;94(4):1641–1649.
   Web of Science ®Google Scholar
• Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS‐CoV‐2 Omicron (B. 1.1. 529) variant of concern and its global perspective. J Med Virol. 2021;94(4):1738–1744.
   Web of Science ®Google Scholar
• Quarleri J, Galvan V, Delpino M. Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. GeroScience. 2021:1–4. doi:10.1007/s11357-021-00500-4
   Web of Science ®Google Scholar
• Gong SY, Chatterjee D, Richard J, et al. Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. Virology. 2021;563:134–145. doi:10.1016/j.virol.2021.09.001
   Web of Science ®Google Scholar
• Pang X, Li P, Zhang L, et al. Emerging SARS-CoV-2 mutation hotspots associated with clinical outcomes and transmission. Front Microbiol. 2021;3047. doi:10.3389/fmicb.2021.753823
   Web of Science ®Google Scholar
• Rao S, Singh M. The newly detected B. 1.1. 529 (Omicron) variant of SARS-CoV-2 with multiple mutations: implications for transmission, diagnostics, therapeutics, and immune evasion. DHR Proc. 2021;1(S5):7–10. doi:10.47488/dhrp.v1iS5.35
   Google Scholar
• Leary S, Gaudieri S, Parker MD, et al. Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid. bioRxiv. 2021;2020:27.
   Google Scholar
• Mourier T, Shuaib M, Hala S, et al. Saudi Arabian SARS-CoV-2 genomes implicate a mutant Nucleocapsid protein in modulating host interactions and increased viral load in COVID-19 patients; 2021.
   Google Scholar
• Benvenuto D, Angeletti S, Giovanetti M, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. J Infect. 2020;81(1):e24–e7. doi:10.1016/j.jinf.2020.03.058
   PubMed Web of Science ®Google Scholar
• Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126–2128. doi:10.1016/S0140-6736(21)02758-6
   PubMed Web of Science ®Google Scholar
• Kannan SR, Spratt AN, Sharma K, et al. Omicron SARS-CoV-2 variant: unique features and their impact on pre-existing antibodies. J Autoimmun. 2022;126:102779. doi:10.1016/j.jaut.2021.102779
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44–57. e9. doi:10.1016/j.chom.2020.11.007
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–424. doi:10.1038/s41579-021-00573-0
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–27. e19. doi:10.1016/j.cell.2020.06.043
   PubMed Web of Science ®Google Scholar
• Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116–121. doi:10.1038/s41586-020-2895-3
   PubMed Web of Science ®Google Scholar
• Volz E, Hill V, McCrone JT, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64–75. e11. doi:10.1016/j.cell.2020.11.020
   PubMed Web of Science ®Google Scholar
• Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757–773. doi:10.1038/s41576-021-00408-x
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum. Lancet. 2021. doi:10.1016/S2352-3018(21)00103-X
   Web of Science ®Google Scholar
• Tada T, Zhou H, Samanovic MI, et al. Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. Biorxiv. 2021. doi:10.1101/2021.07.19.452771
   Google Scholar
• Guerrera G, Picozza M, D’Orso S, et al. BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype. Sci Immunol. 2021;6(66):eabl5344. doi:10.1126/sciimmunol.abl5344
   Web of Science ®Google Scholar
• Wall EC, Wu M, Harvey R, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet. 2021;398(10296):207–209. doi:10.1016/S0140-6736(21)01462-8
   PubMed Web of Science ®Google Scholar
• Anichini G, Terrosi C, Gori Savellini G, et al. Neutralizing antibody response of vaccinees to SARS-CoV-2 variants. Vaccines. 2021;9(5):517. doi:10.3390/vaccines9050517
   Web of Science ®Google Scholar
• Redd AD, Nardin A, Kared H, et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. bioRxiv. 2021. doi:10.1101/2021.12.06.471446
   Google Scholar
• Bošnjak B, Stein SC, Willenzon S, et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol. 2021;18(4):936–944. doi:10.1038/s41423-020-00573-9
   Web of Science ®Google Scholar
• Mengist HM, Kombe AJK, Mekonnen D, et al. editors. Mutations of SARS-CoV-2 spike protein: implications on immune evasion and vaccine-induced immunity. In::Seminars in Immunology. Elsevier; 2021.
   Google Scholar
• Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies (preprint). medRxiv. 2021. doi:10.1101/2021.12.07.21267432
   Google Scholar
• Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-2 Omicron variant (preprint). medRxiv. 2022. doi:10.1101/2021.12.12.21267646
   Google Scholar
• Roessler A, Riepler L, Bante D, et al. SARS-CoV-2 B. 1.1. 529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv. 2021. doi:10.1101/2021.12.08.21267491
   Google Scholar
• Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2021;386(5):492–494.
   Web of Science ®Google Scholar
• Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant omicron. Emerg Microbes Infect. 2021;11:1–11.
   Web of Science ®Google Scholar
• Pulliam JR, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021. doi:10.1101/2021.11.11.21266068
   Google Scholar
• Aggarwal A, Stella AO, Walker G, et al. SARS-CoV-2 Omicron: reduction of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv. 2021. doi:10.1101/2021.12.14.21267772
   Google Scholar
• Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–687. doi:10.1038/s41586-020-2852-1
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182(5):1295–310. e20. doi:10.1016/j.cell.2020.08.012
   PubMed Web of Science ®Google Scholar
• Bertoglio F, Fühner V, Ruschig M, et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations; 2020.
   Google Scholar
• Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292. doi:10.1016/j.cell.2020.02.058
   PubMed Web of Science ®Google Scholar
• Schubert M, Bertoglio F, Steinke S, et al. Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison to the original Wuhan strain and the Beta and Delta variants. medRxiv. 2021. doi:10.1101/2021.12.10.21267523
   Google Scholar
• Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021;2(7):100355. doi:10.1016/j.xcrm.2021.100355
   PubMedGoogle Scholar
• May DH, Rubin B, Dalai SC, et al. Omicron variant partially escapes the T-cell response induced by SARS-CoV-2 vaccines; 2021.
   Google Scholar
• Noh JY, Jeong HW, Kim JH, et al. T cell-oriented strategies for controlling the COVID-19 pandemic. Nat Rev Immunol. 2021;21(11):687–688. doi:10.1038/s41577-021-00625-9
   PubMed Web of Science ®Google Scholar
• Kared H, Redd AD, Bloch EM, et al. SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19 individuals. J Clin Invest. 2021;131(5). doi:10.1172/JCI145476.
   Web of Science ®Google Scholar
• Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. medRxiv. 2021. doi:10.1093/ofid/ofab143
   Google Scholar
• Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829. doi:10.1126/science.abm0829
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID 19 vaccines; 2021.
   Google Scholar
• Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of comirnaty, vaxzevria and spikevax against mild and severe COVID-19 in the UK. medrxiv. 2021. doi:10.1101/2021.09.15.21263583
   Google Scholar
• Ranzani OT, Dos Santos Leite R, Castilho LD, et al. Vaccine effectiveness of Ad26. COV2. S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design. medRxiv. 2021. doi:10.1101/2021.10.15.21265006
   Google Scholar
• Cele S, Jackson L, Khoury DS, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021. doi:10.1101/2021.12.08.21267417
   Google Scholar
• Lu L, Mok BW-Y, Chen L, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. medRxiv. 2021. doi:10.1101/2021.12.13.21267668
   Google Scholar
• Jordan SC, Shin B-H, Gadsden T-AM, et al. T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cell Mol Immunol. 2021;18(11):2554–2556. doi:10.1038/s41423-021-00767-9
   PubMed Web of Science ®Google Scholar
• Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Sci Immunol. 2021;6(59):eabj1750. doi:10.1126/sciimmunol.abj1750
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Sadoff J, et al. Durable humoral and cellular immune responses 8 months after Ad26. COV2. S vaccination. N Engl J Med. 2021;385(10):951–953. doi:10.1056/NEJMc2108829
   PubMed Web of Science ®Google Scholar
• Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184(9):2362–2371. doi:10.1016/j.cell.2021.02.042
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, Denis KS, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–83. e9. doi:10.1016/j.cell.2021.03.013
   PubMed Web of Science ®Google Scholar
• Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med. 2021;386(5):494–6.
   PubMed Web of Science ®Google Scholar
• Basile K, Rockett RJ, McPhie K, et al. Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. bioRxiv. 2021. doi:10.1101/2021.12.12.472252
   Google Scholar
• Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2021;28:1–4.
   Web of Science ®Google Scholar
• Hansen CH, Schelde AB, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: a Danish cohort study. medRxiv. 2021. doi:10.1101/2021.12.20.21267966
   Google Scholar
• Arien KK, Heyndrickx L, Michiels J, et al. Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B. 1.1. 529 (Omicron) variant of concern. medRxiv. 2021. doi:10.1101/2021.12.23.21268316
   Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization–implications for control of the COVID-19 pandemic. Cell. 2021;185(3):447–456.
   PubMed Web of Science ®Google Scholar
• Stamatopoulou M, Tsamadias V, Theodosopoulos T, et al. Rapid decay of anti-SARS-CoV-2 antibodies in infection-naïve healthcare workers four months after vaccination. Germs. 2021;11(4):625. doi:10.18683/germs.2021.1300
   Google Scholar
• Dulovic A, Kessel B, Harries M, et al. Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany. medRxiv. 2021. doi:10.1101/2021.12.01.21266960
   Google Scholar
• Yu X, Wei D, Xu W, et al. Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization. medRxiv. 2021. doi:10.1101/2021.12.17.21267961
   Google Scholar
• Dyer O. Covid-19: south Africa’s surge in cases deepens alarm over omicron variant. BMJ. 2021:n3013. doi:10.1136/bmj.n3013
   Web of Science ®Google Scholar
• Streinu-Cercel A, Săndulescu O, Miron VD, et al. Undetected Omicron transmission in Romania—Report of the first detected case of locally acquired omicron infection and complete epidemiological investigation. Diagnostics. 2022;12(2):348. doi:10.3390/diagnostics12020348
   Web of Science ®Google Scholar
• World Health Organization. COVID-19 situation in the WHO European Region; 2022.
   Google Scholar
• Nishiura H, Ito K, Anzai A, et al. Relative reproduction number of SARS-CoV-2 Omicron (B. 1.1. 529) compared with Delta variant in South Africa. J Clin Med. 2022;11(1):30. doi:10.3390/jcm11010030
   Web of Science ®Google Scholar
• Mahase E. Covid-19: hospital admission 50-70% less likely with omicron than delta, but transmission a major concern. British Medical Journal Publishing Group; 2021.
   Google Scholar
• Yang T-J, Yu P-Y, Chang Y-C, et al. Impacts on the structure-function relationship of SARS-CoV-2 spike by B. 1.1. 7 mutations; bioRxiv. 2021. doi:10.1101/2021.05.11.443686
   Google Scholar
• Leung K, Shum MH, Leung GM, et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance. 2021;26(1):2002106. doi:10.2807/1560-7917.ES.2020.26.1.2002106
   Web of Science ®Google Scholar
• Zuckerman NS, Fleishon S, Bucris E, et al. A unique SARS-CoV-2 spike protein P681H strain detected in Israel. medRxiv. 2021. doi:10.1101/2021.08.21.21262393
   Google Scholar
• Zahradník J, Marciano S, Shemesh M, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol. 2021;6(9):1188–1198. doi:10.1038/s41564-021-00954-4
   PubMed Web of Science ®Google Scholar
• Callaway E, Ledford H. How bad is Omicron? What scientists know so far. Nature. 2021;600(7888):197–199. doi:10.1038/d41586-021-03614-z
   PubMed Web of Science ®Google Scholar
• Herb Scribner. “Doctor reveals new nightly omicron variant symptom”. Deseret News; 2021.
   Google Scholar
• Ferguson N, Ghani A, Cori A, et al. Report 49: growth, population distribution and immune escape of Omicron in England. Imperial College London; 2021.
   Google Scholar
• Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes among patients infected with Omicron (B. 1.1. 529) SARS-CoV-2 variant in southern California. medRxiv. 2022. doi:10.1101/2022.01.11.22269045
   Google Scholar
• Leonhardt D. “Omicron is Milder”. The New York Times; 2022.
   Google Scholar
• Kahn F, Bonander C, Moghaddassi M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities: surveillance results from southern Sweden. medRxiv. 2022. doi:10.2807/1560-7917.ES.2022.27.9.2200121
   Google Scholar
• Scott L, Hsiao N-Y, Moyo S, et al. Track Omicron’s spread with molecular data. Science. 2021;374(6574):1454–1455. doi:10.1126/science.abn4543
   PubMed Web of Science ®Google Scholar
• Metzger CM, Lienhard R, Seth-Smith HM, et al. PCR performance in the SARS-CoV-2 Omicron variant of concern? Swiss Med Wkly. 2021;49:w30120.
   Web of Science ®Google Scholar
• Bal A, Destras G, Gaymard A, et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69–V70, France, August to December 2020. Eurosurveillance. 2021;26(3):2100008. doi:10.2807/1560-7917.ES.2021.26.3.2100008
   Web of Science ®Google Scholar
• Connor Parker. Government scientists monitoring new BA.2 variant of Omicron. Yahoo News; January 21, 2022.
   Google Scholar
• Farooqi T, Malik JA, Mulla AH, et al. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. J Infect Public Health. 2021;14(10):1299–1312. doi:10.1016/j.jiph.2021.08.014
   PubMed Web of Science ®Google Scholar
• FDA. Coronavirus (COVID-19) Update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant; Janaury, 2022.
   Google Scholar
• Miguez-Rey E, Choi D, Kim S, et al. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs. 2022;31:1–18.
   Web of Science ®Google Scholar
• FDA. FDA Roundup: February 25, 2022; February 25, 2022.
   Google Scholar
• Miron VD. COVID-19 in the pediatric population and parental perceptions. Germs. 2020;10(4):294. doi:10.18683/germs.2020.1220
   Google Scholar
• Malik JA, Ahmed S, Mir A, et al. The SARS-CoV-2 mutation versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health. 2022;15(2):228–240. doi:10.1016/j.jiph.2021.12.014
   PubMed Web of Science ®Google Scholar
• Alkandari D, Herbert JA, Alkhalaf MA, et al. SARS-CoV-2 vaccines: fast track versus efficacy. Lancet Microbe. 2021;2(3):e89–e90. doi:10.1016/S2666-5247(21)00034-3
   Google Scholar
• Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine Phase 3 trials. Nat Med. 2021;27(2):205–211. doi:10.1038/s41591-021-01230-y
   PubMed Web of Science ®Google Scholar
• Haveri A, Solastie A, Ekström N, et al. Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults. medRxiv. 2021. doi:10.1101/2021.12.22.21268273
   PubMedGoogle Scholar
• Malik JA, Mulla AH, Farooqi T, et al. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 2021;137:111254. doi:10.1016/j.biopha.2021.111254
   PubMed Web of Science ®Google Scholar